Etoposide%20phosphate
Showing 26 - 50 of 1,776
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small
Recruiting
- Desmoplastic Small Round Cell Tumor
- +11 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Jun 26, 2022
Disseminated Neuroblastoma, Ganglioneuroblastoma, Localized Resectable Neuroblastoma Trial in United States (drug, radiation,
Active, not recruiting
- Disseminated Neuroblastoma
- +5 more
- cyclophosphamide
- +18 more
-
Birmingham, Alabama
- +22 more
Mar 3, 2022
Autologous Stem Cell Transplantation, Conditioning Trial in Xi'an (modified BEAM, BEAM)
Not yet recruiting
- Autologous Stem Cell Transplantation
- Conditioning
- modified BEAM
- BEAM
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xian Jiaotong University
Apr 14, 2023
Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified Trial in United States (radiation, drug,
Completed
- Medulloblastoma
- +2 more
- 3-Dimensional Conformal Radiation Therapy
- +10 more
-
Los Angeles, California
- +14 more
Jan 12, 2022
Extensive Stage Small Cell Lung Cancer Trial (HLX10 + chemo (carboplatin-etoposide), Atezolizumab + chemo
Not yet recruiting
- Extensive Stage Small Cell Lung Cancer
- HLX10 + chemotherapy (carboplatin-etoposide)
- Atezolizumab + chemotherapy (carboplatin-etoposide)
- (no location specified)
Jul 19, 2022
Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)
Recruiting
- Classic Hodgkin's Lymphoma
- Sintilimab
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma Trial
Recruiting
- ENSAT Stage I Adrenal Cortex Carcinoma
- +2 more
- Cisplatin
- +3 more
-
Ann Arbor, Michigan
- +3 more
Dec 13, 2022
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6
Withdrawn
- Recurrent Diffuse Large B-Cell Lymphoma
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor Trial in United States (biological,
Active, not recruiting
- Ovarian Granulosa Cell Tumor
- +6 more
- Bleomycin Sulfate
- +5 more
-
Anchorage, Alaska
- +218 more
Dec 30, 2021
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Tumor, Metastatic Malignant Tumor in the Brain Trial in United States
Active, not recruiting
- Extensive Stage Lung Small Cell Carcinoma
- +2 more
- Atezolizumab
- +3 more
-
New York, New York
- +4 more
Jul 16, 2022
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Seattle
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
- Biopsy
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 8, 2023
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune Trial in Denver, Seattle (biological,
Recruiting
- Autoimmune Disease
- +18 more
- Anti-Thymocyte Globulin
- +9 more
-
Denver, Colorado
- +2 more
Feb 1, 2023
Leukemia Trial in Hershey (Clofarabine, Mitoxantrone, Etoposide)
Terminated
- Leukemia
- Clofarabine
- +2 more
-
Hershey, PennsylvaniaPenn State Hershey Cancer Institute
Jul 22, 2019
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Carboplatin
- +4 more
-
Duarte, California
- +3 more
Oct 24, 2022
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston (drug,
Recruiting
- Extensive Stage Lung Small Cell Carcinoma
- +3 more
- Carboplatin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Nov 8, 2022
Effect of Drug, Toxicity, Drug, Secondary Resistance Trial in Beijing (Apatinib Mesylate, ifosfamide and etoposide)
Completed
- Effect of Drug
- +2 more
- Apatinib Mesylate
- ifosfamide and etoposide
-
Beijing, Beijing, ChinaPeking University People's Hospital
Mar 12, 2022
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma Trial in United
Recruiting
- Acute Adult T-Cell Leukemia/Lymphoma
- +3 more
- Cyclophosphamide
- +5 more
-
Atlanta, Georgia
- +13 more
Jan 26, 2023
Small Cell Lung Cancer Extensive Stage Trial in Spain (Lenvatinib, Pembrolizumab, Etoposide)
Recruiting
- Small Cell Lung Cancer Extensive Stage
- Lenvatinib
- +3 more
-
Badalona, Barcelona, Spain
- +17 more
Jan 26, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Carboplatin
- +5 more
-
Jacksonville, Florida
- +11 more
Jan 12, 2023
Multiple Myeloma, Plasma Cell Tumor Trial in Tampa (etoposide phosphate, melphalan, topotecan)
Completed
- Multiple Myeloma
- Plasma Cell Neoplasm
- etoposide phosphate
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Nov 6, 2019
Small Cell Lung Carcinoma Trial in Omaha (Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in
Terminated
- Small Cell Lung Carcinoma
- Durvalumab + Tremelimumab in combination with carboplatin and etoposide
- Durvalumab in combination with carboplatin and etoposide
-
Omaha, NebraskaUniversity of Nebraska Medical Center
Feb 24, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Extrapulmonary Small Cell Neuroendocrine Carcinoma, Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma, Recurrent
Recruiting
- Advanced Extrapulmonary Neuroendocrine Carcinoma
- +3 more
- Atezolizumab
- +7 more
-
Phoenix, Arizona
- +105 more
Jan 24, 2023